Analysts expect Sarepta Therapeutics, Inc. to report revenue of 332.24 M for Q3 26, against a range of 304.71 M to 359.78 M. The most recent reported quarter, Q2 26, came in at 401.25 M, a 14.6% beat against the 350.28 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 467.17 M | 658.41 M | 744.86 M | 611.09 M | 399.36 M | 442.93 M | 730.80 M | 401.25 M | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 395.15 M | 725.64 M | 774.04 M | 532.72 M | 324.31 M | 369.49 M | 461.27 M | 372.51 M | 359.78 M | 363.64 M | 347.90 M | 393.76 M | 309.77 M | 283.20 M | 396.17 M | 340.88 M | ||||||||||
| Low Estimate | 362.49 M | 615.49 M | 635.46 M | 476.99 M | 302.79 M | 340.95 M | 427.97 M | 328.04 M | 304.71 M | 313.07 M | 319.68 M | 346.65 M | 261.62 M | 263.77 M | 348.57 M | 317.80 M | ||||||||||
| Consensus Estimate | 378.82 M | 670.57 M | 704.75 M | 504.86 M | 313.55 M | 355.22 M | 444.62 M | 350.28 M | 332.24 M | 338.35 M | 333.79 M | 370.21 M | 285.69 M | 273.48 M | 372.37 M | 329.34 M |
Analysts expect Sarepta Therapeutics, Inc. to report earnings per share of 0.17 for Q3 26, against a range of 0.16 to 0.18. The most recent reported quarter, Q2 26, came in at -0.05, a 121.7% miss against the 0.23 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.34 | 1.50 | -4.60 | 1.89 | -1.80 | -3.93 | 2.88 | -0.05 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -0.07 | 1.89 | -3.11 | 0.84 | -0.64 | -1.17 | 0.97 | 0.25 | 0.18 | 0.03 | 0.10 | 0.16 | -0.80 | -0.84 | 0.87 | 0.95 | ||||||||||
| Low Estimate | -0.09 | 1.77 | -3.47 | 0.76 | -0.74 | -1.39 | 0.89 | 0.21 | 0.16 | 0.03 | 0.08 | 0.14 | -0.88 | -0.94 | 0.75 | 0.85 | ||||||||||
| Consensus Estimate | -0.08 | 1.83 | -3.29 | 0.80 | -0.69 | -1.28 | 0.93 | 0.23 | 0.17 | 0.03 | 0.09 | 0.15 | -0.84 | -0.89 | 0.81 | 0.90 |
Pull Wall Street consensus for Sarepta Therapeutics, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=SRPT&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "SRPT", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=SRPT&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();